Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05702-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Georg-Nikolaus Franke und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department for Hematology, Cellular Therapies, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany. Georg-…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Leipzig.
Abstract (Originalsprache)
Clinical trials in chronic myeloid leukemia (CML) are usually carried out in specialized centers whereas primary care for patients (pts) with CML is mainly provided by local oncology practices. The aim of this study was to assess treatment practices in pts with CML in the setting of private oncology practices in Germany. We collected data of 819 pts with a confirmed diagnosis (dx) of CML in 2013 or later from 43 practices. At dx, 84.2% ( n =690) and 9.4% ( n =77) of pts were in chronic or accelerated phase, 0.7% ( n =6) had a blast crisis. Molecular monitoring was provided by EUTOS certified laboratories in 87.7% of pts. Typical BCR::ABL1 transcripts were detected in 86.6% ( n =709). Molecular response was assessed after 2.8, 6.0, 9.4 and 12.9 m (mean) after start of treatment. Of the pts with available data, 11.1% did not achieve early molecular response and at 18 m, 83.7% had at least a major molecular response. 288 (35.2%) of pts switched to 2 nd line (2L) treatment after a mean of 21.0 months. Reasons for 2L treatment were side effects in 43.4% and suboptimal response or failure in 31.4% of pts. 106 pts went on to third line (3L) treatment. 36.8 % of pts switched to and 92.8 % of pts still on 3L treatment achieved BCR::ABL1 IS ≤1% at 12 m. In conclusion, in Germany pts with CML are routinely monitored by qPCR and good responses are achieved in the majority. Treatment changes are mainly due to adverse events rather than suboptimal responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Hematology, Cellular Therapies, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany. Georg-nikolaus.franke@medizin.uni-leipzig.de.
- Novartis Pharma GmbH, Nuremberg, Germany.
- PIOH-Zentrum Praxis Internistischer Onkologie und Hämatologie, Cologne, Germany.
- MVZ für Blut- und Krebserkrankungen, Potsdam, Germany.
- Schwerpunktpraxis für Onkologie, Gastroenterologie, Hämatologie und Palliativmedizin, Berlin, Germany.
- Studienzentrum am Raschplatz GbR, Hannover, Germany.
Förderung
- Universität Leipzig
Zitieren
APA
Franke, G. N., Loewe, G., Reiser, M., Linde, H., Josting, A., von der Heyde, E., Platzbecker, U., Weide, R., Tesch, H., Nusch, A., Dengler, J., & Jentsch-Ullrich, K. (2024). Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices. Annals of Hematology. https://doi.org/10.1007/s00277-024-05702-2
Vancouver
Franke GN, Loewe G, Reiser M, Linde H, Josting A, von der Heyde E, et al. Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices. Annals of Hematology. 2024. doi:10.1007/s00277-024-05702-2
BibTeX
@article{Franke2024,
author = {Franke, Georg-Nikolaus and Loewe, Gunnar and Reiser, Marcel and Linde, Hartmut and Josting, Andreas and von der Heyde, Eyck and Platzbecker, Uwe and Weide, Rudolf and Tesch, Hans and Nusch, Arndt and Dengler, Jolanta and Jentsch-Ullrich, Kathleen},
title = {Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05702-2}
}
EUVIMED